The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation

American Journal of Transplantation

Volumn 4, Issue 6, 2004, Pages 914-919

  MacPhee, Iain A M ^a   Fredericks, Salim ^a   Tai, Tracy ^a   Syrris, Petros ^a   Carter, Nicholas D ^a   Johnston, Atholl ^b   Goldberg, Lawrence ^c   Holt, David W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UK   (United Kingdom)

Author keywords

CYP3A5; Pharmacogenetics; Renal transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; CYTOCHROME P450 3A1; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; TIME FACTORS;

EID: 2942588886     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00435.x     Document Type: Article

References (31)

1. MacPhee IAM, Fredericks S, Tai T et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-1489.
2. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001; 16: 1905-1909.
3. Undre NA, van Hoof J, Christiaans M et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296-298.
4. Bottiger Y, Brattstrom C, Tyden G, Sawe J, Groth C-C. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. B J Clin Pharmacol 1999; 48: 445-448.
5. Karanam BV, Vincent SH, Lee Chiu SH. FK506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isoenzymes other than CYP3A4. Drug Metab Dispos 1994; 22: 811-814.
6. Andrews PA, Sen M, Chang RWS. Racial variation in dosage requirements of tacrolimus. Lancet 1996; 348: 1446.
7. Neylan JF. Racial Differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65: 515-523.
8. Mancinelli LM, Frassetto L, Floren LC et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24-31.
9. Felipe CR, Machado PGP, Garcia R, da Silva Moreira SR, Pestana JOM. The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin Transplant 2003; 16: 262-272.
10. Eiselt R, Domanski TL, Zibat A et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001; 11: 447-458.
11. Garcia-Martin E, Martinez C, Pizarro RM et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002; 71: 196-204.
12. Min DI, Ellingrod VL. Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2003; 25: 305-309.
13. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048-1052.
14. Rivory LP, Qin H, Clarke SJ et al. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. Eur J Clin Pharmacol 2000; 56: 395-398.
15. Goldammer EM, Mai I, Roots I et al. No influence of the MDR-1 C3435T polymorphisms, the CYP3A4-V-allele or the CYP3A5*3 polymorphism on cyclosporine absorption profiles and outcome in stable renal transplant recipients. Am J Transplant 2003; 3 (Suppl. 5): 425.
16. Hesselink DA, van Schaik RH, van der Heiden I et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol. Ther 2003; 74: 245-254.
17. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000; 260: 13-23.
18. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
19. Lin YS, Dowling AL, Quigley SD et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-172.
20. Hustert E, Haberl M, Burk O et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
21. van Schaik RHN, van der Heiden LP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48: 1668-1671.
22. Zheng HX, Webber S, Zeevi A et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3: 477-483.
23. Zheng HX, Zeevi A, Lamba J et al. Tacrolimus nephrotoxicity is predicted by MDR1 exon 21 gene polymorphism while dosing is predicted by cytochrome P4503A5 polymorphism in adult lung transplant patients. Am J Transplant 2003; 3 (Suppl. 5): 426.
24. Thervet E, Anglicheau D, King B et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233-1235.
25. Anglicheau D, Verstuyft C, Laurent-Puig P et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889-1896.
26. Fredericks S, Holt DW, MacPhee IAM. The pharmacogenetics of immunosuppression for organ transplantation. Am J Pharmacogenomics 2003; 3: 291-301.
27. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporin microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024-1032,
28. Clase CM, Mahalati K, Kiberd BA et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2: 789-795.
29. Ameyaw M-M, Regateiro F, Li T et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221.
30. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
31. Yates CR, Zhang W, Song P et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharm 2003; 43: 555-564.